UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 115

Sortiert nach

AKT in cancer: new molecular insights and advances in drug development

British journal of clinical pharmacology, 2016-10, Vol.82 (4), p.943-956

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

British journal of cancer, 2020-05, Vol.122 (11), p.1630-1637

2020

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

Clinical cancer research, 2019-11, Vol.25 (21), p.6309-6319

2019

Link zum Volltext

Verfügbarkeit prüfen

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2804-2811

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Clinical cancer research, 2016-07, Vol.22 (13), p.3157-3163

2016

Link zum Volltext

Verfügbarkeit prüfen

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

Clinical cancer research, 2017-07, Vol.23 (14), p.3638-3648

2017

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Clinical cancer research, 2021-08, Vol.27 (16), p.4511-4520

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

Breast cancer research and treatment, 2021-02, Vol.185 (3), p.759-771

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

British journal of clinical pharmacology, 2020-09, Vol.86 (9), p.1836-1848

2020

Link zum Volltext

Verfügbarkeit prüfen

Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective

Clinical breast cancer, 2016-04, Vol.16 (2), p.73-81

2016

Link zum Volltext

Verfügbarkeit prüfen

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Clinical cancer research, 2022-08, Vol.28 (15), p.3214-3224

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Clinical cancer research, 2021-01, Vol.27 (2), p.447-459

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

Clinical cancer research, 2016-02, Vol.22 (4), p.827-836

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

Cancer chemotherapy and pharmacology, 2022-01, Vol.89 (1), p.93-103

2022

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors

Investigational new drugs, 2020-12, Vol.38 (6), p.1815-1825

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy

Breast cancer research and treatment, 2020-10, Vol.183 (3), p.617-627

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

JAMA oncology, 2021-02, Vol.7 (2), p.271

2021

Link zum Volltext

Verfügbarkeit prüfen

Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer

Clinical breast cancer, 2012-02, Vol.12 (1), p.19-29

2012

Link zum Volltext

Verfügbarkeit prüfen

Multiple Gastrointestinal Symptoms Are Associated With Chemotherapy-Induced Nausea in Patients With Breast Cancer

Cancer nursing, 2022-05, Vol.45 (3), p.181

2022

Link zum Volltext

Verfügbarkeit prüfen

Evolution of Bevacizumab-Based Therapy in the Management of Breast Cancer

Clinical breast cancer, 2008-10, Vol.8 (5), p.402-410

2008

Link zum Volltext

Verfügbarkeit prüfen

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e003924

2022

Link zum Volltext

Verfügbarkeit prüfen

Update on Precision Medicine in Breast Cancer

Cancer treatment and research, 2019, Vol.178, p.45-80

2019

Link zum Volltext

Verfügbarkeit prüfen

Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer

Radiology. Imaging cancer, 2023-03, Vol.5 (2), p.e220022-e220022

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT046: First-in-human phase 1 study assessing imalumab (BAX69), an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT046-CT046

2016

Link zum Volltext

Verfügbarkeit prüfen

Dantrolene sodium for the treatment of aldesleukin-induced rigors in a melanoma patient

The Annals of pharmacotherapy, 2012-05, Vol.46 (5), p.e11

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(114)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(114)
Buchkapitel
(1)

Sprache

Englisch
(115)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Oncology
(32)
Humans
(30)
Female
(23)
Middle Aged
(19)
Adult
(15)
Aged
(15)
Male
(14)
Neoplasms - Drug Therapy
(11)
Tumors
(11)
Aged, 80 And Over
(10)
Breast Cancer
(9)
Solid Tumors
(9)
Treatment Outcome
(9)
Antineoplastic Agents - Therapeutic Use
(8)
Breast Neoplasms - Drug Therapy
(8)
Patients
(8)
Cancer Research
(7)
Medicine
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

AKT in cancer: new molecular insights and advances in drug development

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors

Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase

Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours

Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial

A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors

Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

Blockade of the HER Family of Receptors in the Treatment of HER2-Positive Metastatic Breast Cancer

Multiple Gastrointestinal Symptoms Are Associated With Chemotherapy-Induced Nausea in Patients With Breast Cancer

Evolution of Bevacizumab-Based Therapy in the Management of Breast Cancer

IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin–paclitaxel, with or without bevacizumab in patients with advanced cancer

Update on Precision Medicine in Breast Cancer

Pretherapy Ferumoxytol-enhanced MRI to Predict Response to Liposomal Irinotecan in Metastatic Breast Cancer

Abstract CT046: First-in-human phase 1 study assessing imalumab (BAX69), an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors

Dantrolene sodium for the treatment of aldesleukin-induced rigors in a melanoma patient

Suchergebnisse filtern